PBAC rejects dupilumab for eczema

There’s been a win and a loss for dermatology patients in outcomes from the July PBAC meeting which were made public last week. The Committee recommended Authority Required PBS listing of risankizumab  – an anti-IL23A antibody biologic – for patients with severe chronic plaque psoriasis. However it has, for the second time, rejected dupilumab – ...

Already a member?

Login to keep reading.

© 2021 the limbic